📢 Paper highlight: How might PPARγ help limit liver fibrosis? PPARγ increased senescence markers and reduced fibrosis-associated markers in hepatic stellate cells, via LIFR and reduced STAT3 phosphorylation. Rosiglitazone also reduced fibrosis-associated changes in mice. Paper in reply ↓

Ever had a client question an unexpected protein quantification result? The assay passes QC, but can the reference material support the interpretation? ¹⁵N-labelled full-length protein standards, added before sample prep, can help account for losses before digestion. More on our website or by DM.

A good SNCA pS129 antibody isn’t automatically a good pair. In sandwich assays, capture and detection antibodies must work together. For low-abundance, site-specific pS129, pairing matters. That’s why we test SNCA pS129 antibodies in both orientations with P2P2P™. 8 pairs: ES-5502–ES-5509.

📢 Publication highlight: How do plant cells protect membranes from heat? In rice, OsALA5 rapidly flips saturated phosphatidylcholines to stabilize membrane fluidity and limit cell damage. A custom Absea antibody helped characterize OsALA5 expression and localization.

A good α-syn antibody pair on recombinant protein may behave differently in biological samples. P2P2P™ tests candidate pairs beyond standard protein, including in complex samples. 8 α-syn pairs are now available, validated across both. #AlphaSynuclein #ParkinsonsDisease

📢Publication highlight: How does an innate immune response connect to haemocyte proliferation? A Comparative Immunology Reports study found that CgIRF1 knockdown reduced EdU-positive haemocytes to ~37% of control levels in Crassostrea gigas. Absea anti-IRF1 RC-5332 was used for WB and IF.

Mass spec isn't the bottleneck in TF interactomics. Protein supply is. Markku Varjosalo's team at the University of Helsinki tested our recombinant TF proteins and went straight to the native holdup. Here's what they had to say 👇 #TranscriptionFactors #Interactomics

#HUPO2026 is a wrap. Five days in Singapore, many conversations with the proteomics community about their work, current challenges and where proteomics is heading. Thank you to everyone who stopped by Booth 227 and exchanged ideas with the team. #Proteomics #MassSpectrometry

Abby made it to #HUPO2026 And of course, Abby is already getting some attention at Booth 227. Some of you have already stopped by looking for one. Good news: we still have a few Abbys with us. So if you’re still at HUPO, you might leave with more than just brochures and flyers. 👀 #Proteomics

A few days into #HUPO2026 It’s been great to see familiar faces, meet new ones and hear what people are working on. We’re still at Booth 227 until Thursday. Come find us if you’re at HUPO 👋 #Proteomics #MassSpectrometry

Today at #HUPO026. Ying Zhu will present our latest work on high-throughput crosslinking-MS and large-scale interactome analysis from intact human cells. Poster PS01.194 2:00 PM – 3:00 PM #Proteomics #teammassspec

HUPO 2026 starts today! 🇸🇬 Clement, Ying and Phoebe are in Singapore and ready for a few days of conversations around proteins, antibodies and mass spectrometry. N-15 labeled proteins, Architectomics™, P2P2P™ and HybrMax™ are all part of the conversation. Come find us at Booth 227 👋 #HUPO2026

Antibody and MS assays can study the same protein, but they answer different questions. Antibodies offer sensitivity, throughput and epitope-specific recognition. MS gives peptide-level information. So why should quantitative MS rely on a single peptide as its reference? #Proteomics

How far can human interactome analysis be pushed in 24 hours? Ying Zhu will share our latest work at #HUPO2026 on high-throughput crosslinking-MS workflows and large-scale interactome analysis from intact human cells. Poster PS01.194 Monday | 2:00 PM – 3:00 PM Booth #227 See you soon!

We’re heading to HUPO 2026 in Singapore 🇸🇬 We’ll be at Booth 227 from Sept. 27–Oct. 1, sharing some of the work we’ve been doing around proteins, antibodies and mass spectrometry. If you’re coming to HUPO, come find us. We’d love to meet you and hear what you’re working on. More info👇 #HUPO2026

Our SVP Philip Lössl joined an AI in Biotechnology panel at Berlin yesterday, good conversation on where AI might actually helps. Two things we work on speak to that: SIEVE® (making molecules) and Architectomics® (mapping molecules, helping fill data gaps for models). DM us for more informations!

pTau217 is a core AD blood #biomarker. What can other tau phosphorylation sites add? Brain-tissue studies suggest pSer396 rises mainly at later Braak stages, alongside more widespread cortical tau pathology. Absea’s #pTau396 pairs are evaluated using protein standards and biological samples. 🧪

In plasma, pTau199 shows a distinct profile from pTau181 and pTau217. Autopsy data link plasma pTau199 to lower brain weight and shorter survival in AD-predominant cases. Absea pairs are assessed in protein standards and biological samples. 👇 #pTau199

Interesting paper in npj Parkinson’s Disease: the researchers compared the same biomarkers in serum and extracellular vesicles across Parkinson’s, PSP and MSA. The EV measurements generally showed stronger discrimination than the matched serum measurements. #ParkinsonsDisease #Biomarkers

APOE ε4 status now informs ARIA-risk discussions for anti-amyloid therapy. But ApoE4 protein-assay development remains challenging: the isoforms differ by just one amino acid, and biological matrices are complex. Our P2P2P workflow: recombinant protein → biological samples. 🧪 #APOE4 #Biomarkers

A promising biomarker in discovery is one thing. Quantifying it in validation is another. Once you need a concentration, what is it based on? A good full-length reference isn't always easy to find. ¹⁵N-labeled proteins provide a distinguishable one — part of the library we're working on at Absea.

A positive ELISA only tells you a clone binds the target. Not whether it'll work in WB, IHC, or flow. HybrMax™ tests application fit on hybridoma supernatant early, before expression, while sequencing runs in parallel.

📢Publication highlight: Maslinic acid increased autophagy and ferroptosis in MDA-MB-231 cells. NCOA4 knockdown → less FTH1 degradation → weaker ferroptotic response. A link between ferritinophagy and ferroptosis. Absea anti-FTH1 & anti-SLC7A11 antibodies were used. DOI ↓ doi.org/10.21037/tcr...

NCOA4-driven ferritinophagy and GSH reprogramming underlie maslinic acid-induced ferroptosis and autophagy in breast cancer

NCOA4-driven ferritinophagy and GSH reprogramming underlie maslinic acid-induced ferroptosis and autophagy in breast cancer

doi.org

Planning a protein–protein or protein–ligand interaction study? Architectomics™ maps binding partners, interfaces, and on- and off-target affinities across the proteome—in one experiment. Answer a few questions for a tailored plan and cost estimate, free and without obligation ↓

Detecting low-abundance CCL17 can make antibody-pair performance critical for immunoassay development Our ES-5482 just showed clear antigen-dependent signal, low background, and a concentration-dependent response by flow cytometry. Working on a CCL17 assay? See our validation data ↓

Can immunotherapy make tumors more resistant? A new Immunity study identifies the ATP–P2RY2–PGE₂ axis as one mechanism of adaptive resistance to immunotherapy. The researchers used Absea's Cas9-GFP reagent as part of their CRISPR editing workflow. ↓ Paper + DOI 10.1016/j.immuni.2026.06.006

An ADC PK result looks off — biology, or the assay? Peptide standards added after digestion can't report earlier variability. A standard can only tell you about the steps it actually went through. That's the principle behind the ¹⁵N-labeled standards we're developing at Absea. #ADC #MassSpec

pTau217 works well as an Alzheimer's blood biomarker. So why look at pTau212? Studies suggest similar performance, but separating it from pTau217 without cross-reactivity is the assay challenge. pTau212 is now part of our tau portfolio, covering 50+ phosphorylation sites. ↓ Paper + product

A new immune evasion regulator in liver cancer — STK40. Its loss combined with anti-PD-1 led to complete tumor regression in preclinical models. Absea's anti-STK40 antibody supported validation throughout. Zhu et al., Cancer Cell 2026. ↓link in comment #Immunotherapy #CancerResearch #Oncology

June was a busy month. From conferences and scientific discussions to ongoing R&D, June kept us moving. We rounded it off with our annual team event on the Spandauer See. Thanks to everyone we met at ASMS, bio:cap Berlin, Drug Discovery Europe and the HRMS Symposium! #biotech #teammassspec